MULTIPLE OUTCOMES. ONE VALUE-CREATION DISCIPLINE.
Proof belongs in the numbers.
Straterra's work is measured by outcomes that matter: runway extended, valuation drivers strengthened, transactions prepared, R&D cashflow improved, and enterprise value defended.
We publish only what we are able to verify and what our clients are comfortable referencing. Where mandates remain confidential, outcomes may be summarised without disclosing the underlying company.
Headline Outcomes
USD $443M+
Combined exit value delivered.
3 major exits
Experience across completed transaction outcomes with globally recognised results.
AUD $200M+
Cashflow and operating resilience delivered via Australian R&D Tax Incentive optimisation.
Selected Straterra facilitated outcomes
Each case below summarises sector, approaches deployed, Straterra’s contribution, and the outcome delivered. Some details are intentionally summarised for confidentiality.
MEDTECH
Biorez
CLIENT
Biorez is an international Health/MedTech organisation located within the business precinct of Yale University New Haven, USA, and developer of the BioBrace®, a reinforced bioinductive implant that was acquired by Conmed in 2022.
APPROACHES DEPLOYED
Australian R&D operations. Value Creation Retainer. Transaction Preparation.
OUR WORK
Established Biorez’s Australian entity. Leadership and management of Biorez Pty Ltd. Delivery of accounting, bookkeeping and compliance functions. Management of the Risk Management System, Intercompany IP agreement and R&D program. Liaison with Conmed throughout the due diligence process.
OUTCOMES DELIVERED
510K clearance of Biorez’s Bio Brace technology following preclinical trials conducted at the University of NSW.
Acquired by Conmed (NYSE-CNMD) in August 2022 for USD$85M.
EXTERNAL LINKS
LIFE SCIENCES
Theracell
CLIENT
TheraCell is focused on the development of advanced technologies for bone and soft tissue repair and is the inventor of the next-generation,TheraFuze DBF® demineralized bone fiber technology. Founded in 2008, the firm operates is clinical headquarters from Melbourne, Australian with global headquarters based in Los Angeles.
APPROACHES DEPLOYED
Value Readiness Assessment | Cash Runway Extension | Value Creation Retainer | Transaction Preparation | Australian R&D operations
OUR WORK
Established Theracell’s Australian entity. Leadership and management of Theracell Labs Pty Ltd. Delivery of accounting, bookkeeping and compliance functions. Management of the Risk Management System, Intercompany IP agreement and R&D program. Liaison with IstoBiologics throughout the due diligence process.
OUTCOMES DELIVERED
510K clearance of Theracell’s technology following preclinical trials conducted at the University of NSW.
Acquired by Istobiologics in April 2022.
EXTERNAL LINKS
DIGITAL HEALTH
Volpara
CLIENT
Volpara Health (now part of Lunit) is a medical software company specialising in AI-powered tools for breast cancer screening, risk assessment, and early detection. Their platform helps radiologists quantify breast tissue density, optimise mammogram image quality, and identify high-risk patients for personalised care.
APPROACHES DEPLOYED
Board Directorship, including membership of the Audit and Risk Committees. Membership of Exit Strategy Team.
OUR WORK
Founder and CEO, Mark Bouw was engaged as a Director of Volpara Health (ASX-VHT) on January 2022 with a market cap of $42M. Mark was involved in the exit strategy team.
OUTCOMES DELIVERED
Volpara Health Technologies successfully exited as a public company in May 2024 when it was acquired by South Korean AI medtech company Lunit in an all-cash deal.
EXTERNAL LINKS
Some mandates remain confidential.
Where a mandate is bound by confidentiality, Straterra summarises the work and outcome without disclosing the underlying company. The discipline behind the work is the same.